Markets:

Overview

News

Currencies

International

Treasuries

AdvisorShares Psychedelics ETF (NY:PSIL)

20.44 -0.40 (-1.91%)

Streaming Delayed Price Updated: 9:32 AM EDT, Jun 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AdvisorShares Psychedelics ETF

< Previous 1 2 3 4 5 Next >

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗

January 12, 2024

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Via Benzinga

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗

January 07, 2024

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

Via Benzinga

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Psychedelic Drug Stocks Index Up In December; Down YTD ↗

December 27, 2023

The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021.

Via Talk Markets

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗

December 18, 2023

Biden To Decide On Psychedelic Therapy Bill

Via Benzinga

Psychedelic Drug Stocks Index Declined 1.6% This Week ↗

December 17, 2023

Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD.

Via Talk Markets

Topics ETFs

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗

December 11, 2023

John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy

Via Benzinga

5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week ↗

December 10, 2023

The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.

Via Talk Markets

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗

December 05, 2023

Defense Dept. Funds Ketamine Study For PTSD Treatment

Via Benzinga

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗

November 24, 2023

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

Via Benzinga

Topics Cannabis

GH Research Drags Down Psychedelic Drug Stocks Index By 7% ↗

November 23, 2023

The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week.

Via Talk Markets

Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗

November 12, 2023

Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?

Via Benzinga

Topics Initial Public Offering

Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗

November 06, 2023

DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court

Via Benzinga

Topics Economy

Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗

October 29, 2023

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Via Benzinga

Topics Intellectual Property

Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗

October 22, 2023

Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts

Via Benzinga

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗

October 16, 2023

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution

Via Benzinga

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗

October 06, 2023

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

Via Benzinga

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

September Summary: Largest Psychedelic Drug Stocks Dropped 14% ↗

October 01, 2023

Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining...

Via Talk Markets

EXCLUSIVE: What's Next For Cannabis? Industry Experts Discuss Game-Changing New Policies ↗

September 27, 2023

Cannabis reform has moved one step closer to reality at the federal level on Wednesday, with the Senate Banking Committee approving the Secure and Fair Enforcement Regulation (SAFER) Banking Act.

Via Benzinga

Topics Cannabis

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price ↗

September 24, 2023

With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and...

Via Talk Markets

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗

September 18, 2023

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

Via Benzinga

4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week ↗

September 17, 2023

4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week...

Via Talk Markets

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

6 Largest Psychedelic Compound-Based R & D Stocks In Decline ↗

September 10, 2023

The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD.

Via Talk Markets

6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week ↗

September 05, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD.

Via Talk Markets

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗

September 05, 2023

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

Via Benzinga

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗

August 28, 2023

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

Via Benzinga

The 7 ETFs In The Fringe Portfolio Were, On Average, Up Last Week ↗

August 27, 2023

If you are interested in any of the cannabis, psychedelic, Bitcoin, AI,

Via Talk Markets

Topics Artificial Intelligence Cannabis ETFs

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.